Investing.com - Arrowhead Pharma reported on Monday fourth quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Arrowhead Pharma announced earnings per share of $-0.80 on revenue of $31.57M. Analysts polled by Investing.com anticipated EPS of $-0.42 on revenue of $44.86M.
Arrowhead Pharma shares are down 57% from the beginning of the year , still down 62.55% from its 52 week high of $74.77 set on Wednesday, December 8, 2021.
Arrowhead Pharma follows other major Healthcare sector earnings this month
Arrowhead Pharma's report follows an earnings beat by Eli Lilly on Tuesday, November 1, 2022, who reported EPS of $1.98 on revenue of $6.94B, compared to forecasts EPS of $1.91 on revenue of $6.91B.
Pfizer had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.78 on revenue of $22.6B, compared to forecast for EPS of $1.44 on revenue of $21.33B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar